DCX Liquid Cooling Systems Announces New 8MW Coolant Distribution Unit, Optimized for 45°C Warm-Water Cooling in Next-Gen NVIDIA Vera Rubin AI Deployments

23.1.2026 14:18:00 CET | Business Wire | Press Release

DCX Liquid Cooling Systems is proud to announce the second generation Facility Distribution Unit (FDU V2AT2). Designed to support the infrastructure shift driven by AI deployments at scale, new CDU supports 45°C warm-water cooling for NVIDIA’s NVL72 GB200 / GB300 Blackwell and Vera Rubin architectures.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260123068139/en/

The Facility Coolant Distribution Unit—the new generation of liquid cooling for hyperscale data centers.

FDU V2AT2 delivers up to 8.15MW of heat transfer capacity while providing record breaking flowrate, enabling 45°C warm-water operation—temperature level that can eliminate the need for chillers on the heat-rejection side in many deployments. This new cooling system has also built in most capable heat exchanger in the industry, which further enables heat reuse and chillerless heat transfer.

“As the datacenter industry transitions to AI factories, operators need cooling system that won’t be obsolete in one platform cycle,” said Maciek Szadkowski, CTO at DCX. “The FDU V2AT2 replaces multiple legacy 1.3MW CDUs and enables 45°C supply water operation. This new category of CDUs has minimum thermal loss with AT2 approach temperature, and provides multi-megawatt cooling at the hall level. That opens a clear path to NVIDIA Vera Rubin architecture and beyond while simplifying cooling loop topology and significantly reducing both CAPEX and OPEX of datacenter liquid cooling system.”

Purpose-Built for 45°C Warm Water and Chillerless Heat Rejection

NVIDIA has highlighted 45°C water supply as a key design point for Vera Rubin rack-scale systems—explicitly enabling data centers to operate without traditional water chillers in the cooling plant for these workloads.

The DCX FDU V2AT2 is engineered to take full advantage of that shift by supporting ASHRAE W45 / W+ warm-water classes and maintaining tight control to avoid condensation, helping operators move from refrigeration-centric cooling to a simpler, more scalable warm-water approach.

From “Row CDU” to Facility-Scale Distribution

Unlike CDUs designed for a single row or small cluster, the FDU 2 is engineered for a new cooling topology that supports complete data halls / facility installations, efficiently supporting large-scale, high-density AI server racks with high flow, high availability and sustainable 45°C temperature class operation.

Key capabilities include:

Industry record 8.15MW heat transfer (cooling) capacity, supporting hyperscale AI growth
Record breaking 550 m³/h flow rate required by 45°C warm-water cooling supporting chillerless heat rejection strategies
Most capable heat exchanger in CDU with 2°C approach temperature for heat reuse and low cost heat rejection
4 pumps in N+1 redundant configuration for high availability
Built in comprehensive water quality control in line sensors and water treatment system

Availability

The DCX FDU V2AT2 is available for hyperscale and high-density AI data center projects effective immediately. Reference architectures, integration guidance, and project sizing support are available upon request.

About DCX Liquid Cooling Systems

DCX Liquid Cooling Systems is a premier global manufacturer offering an extensive range of sustainable liquid cooling solutions, including both Direct Liquid Cooling and Immersion Cooling technologies. The company designs & manufactures Server Immersion Enclosures, Coolant Distribution Units (CDUs) including Hyperscale FDU (facility sized CDU) systems, CPU and GPU coldplates, manifolds and other components of liquid cooling system. DCX delivers Hydro & Immersion Containers and facility-based systems. Hardware solutions are complemented with liquid cooled data hall design and implementation services, making DCX the first choice for liquid cooling systems’ supplier.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260123068139/en/

Contacts

Jacek Dolny, Head of Marketing
mobile: +48 722 121 255
jacek.dolny@dcx.eu

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press Release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press Release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press Release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press Release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom